Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HHS opposes pediatric legislation

This article was originally published in The Gray Sheet

Executive Summary

HHS Secretary Michael Leavitt is expressing "major concerns" about pediatric device language in the FDA Revitalization Act (S 1082), which cleared the Senate Health, Education, Labor and Pensions Committee April 18. In an April 17 letter to HELP Chairman Sen. Edward Kennedy, D-Mass., Leavitt writes that HHS opposes provisions that sanction government funding of research run by private consortia and allow firms to profit from devices approved under a humanitarian device exemption. The pediatric device section of the bill is intended to offer incentives to manufacturers to develop devices for children and adolescents (1"The Gray Sheet" April 2, 2007, p. 25). Amendments could be added to the legislation, which also includes provisions reauthorizing medical device and pharmaceutical user fee programs, before the full Senate votes on the measure...

You may also be interested in...

Dodd Aims For Quick Passage Of Pediatric Device Legislation

Sen. Christopher Dodd, D-Conn., is pushing for quick action on legislation to provide incentives for the development of pediatric medical devices

FDA Officials Cite Reasons For Denying Application Reviews Over Data Integrity Breaches

Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.

Vaccinex Sees Mixed Signals In Huntington’s Study

However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts